Post-COVID Syndrome Program

About StemCyte

StemCyte is an established leader in the cord blood banking and regenerative medicine sector, uniquely positioned with a dual private/public banking model. The company has a strong clinical footprint, having provided units for 1 out of every 26 cord blood transplants worldwide and actively participating in numerous clinical trials. A significant recent milestone is the U.S. FDA approval of its Biologics License Application (BLA) for REGENECYTE™, marking its transition into a commercial-stage cell therapy developer. StemCyte's integrated approach—from biobanking to advanced therapy development—creates a vertically differentiated platform in the cellular therapeutics space.

Therapeutic Areas